Global Nanomaterial-Based Adjuvants Vaccine Market Size, Share, Trends and Forecast 2022-2030

Description

Market Analysis and Insights: Global Nanomaterial-Based Adjuvants Vaccine Market
Due to the COVID-19 pandemic, the global Nanomaterial-Based Adjuvants Vaccine market size is estimated to be worth US$ 25770 million in 2022 and is forecast to a readjusted size of US$ 40890 million by 2028 with a CAGR of 8.0% during the review period. Fully considering the economic change by this health crisis, Aluminium Hydroxides accounting for % of the Nanomaterial-Based Adjuvants Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Pneumococcus segment is altered to an % CAGR throughout this forecast period.

Global key players of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, Sanofi, etc. Global top 3 companies hold a share over 80%. North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%. In terms of product, Lipidosome is the largest segment, with a share about 80%. And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.

Market Segments

The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.

Segment by Type

Aluminium Hydroxides

Aluminium Phosphate

Lipidosome

Others

Segment by Application

Pneumococcus

Human Papilloma Virus

DTaP

Viral Hepatitis TypeA

Viral Hepatitis TypeB

SARS-CoV-2

Others

Consequence of Covid-19 Pandemic

The authors of this study have enlightened the readers on the rise and effect of the Covid-19 outbreak on the development. They have investigated the changes brought about in the demand/supply side, consumption, supply chain, and sales/manufacturing. The readers will get familiar with the measures that have helped the key players to bring the Nanomaterial-Based Adjuvants Vaccine market back to the pre-covid levels.

Trends & Prospects

In this segment of the report, the specialists have delved into the key growth opportunities that are likely to emerge. This will aid the key players to simplify complex issues related to business and frame future strategies to compete in this competitive environment. This section will certainly assist the players to boldly position their business.

By Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Outlook

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and share analysis of the prominent players are also provided in this section. They have also provided reliable sales and revenue data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

Emergent BioSolutions

Sanofi

GlaxoSmithKline Biologicals

Merck

Pfizer

Novartis

Moderna

TABLE OF CONTENT

1 Study Coverage
1.1 Nanomaterial-Based Adjuvants Vaccine Product Introduction

1.2 Market by Type

1.2.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Aluminium Hydroxides

1.2.3 Aluminium Phosphate

1.2.4 Lipidosome

1.2.5 Others

1.3 Market by Application

1.3.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Pneumococcus

1.3.3 Human Papilloma Virus

1.3.4 DTaP

1.3.5 Viral Hepatitis TypeA

1.3.6 Viral Hepatitis TypeB

1.3.7 SARS-CoV-2

1.3.8 Others

1.4 Study Objectives

1.5 Years Considered

2 Executive Summary

2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Estimates and Forecasts 2017-2028

2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue Estimates and Forecasts 2017-2028

2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2017 VS 2021 VS 2028

2.4 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region

2.4.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (2017-2022)

2.4.2 Global Sales Nanomaterial-Based Adjuvants Vaccine by Region (2023-2028)

2.5 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region

2.5.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2017-2022)

2.5.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2023-2028)

2.6 North America

2.7 Europe

2.8 Asia-Pacific

2.9 Latin America

2.10 Middle East & Africa

3 Competition by Manufacturers

3.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Manufacturers

3.1.1 Global Top Nanomaterial-Based Adjuvants Vaccine Manufacturers by Sales (2017-2022)

3.1.2 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers (2017-2022)

3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Nanomaterial-Based Adjuvants Vaccine in 2021

3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Manufacturers

3.2.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Manufacturers (2017-2022)

3.2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Manufacturers (2017-2022)

3.2.3 Global Top 10 and Top 5 Companies by Nanomaterial-Based Adjuvants Vaccine Revenue in 2021

3.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Price by Manufacturers (2017-2022)

3.4 Analysis of Competitive Landscape

3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Nanomaterial-Based Adjuvants Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4.3 Global Nanomaterial-Based Adjuvants Vaccine Manufacturers Geographical Distribution

3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type

4.1.1 Global Nanomaterial-Based Adjuvants Vaccine Historical Sales by Type (2017-2022)

4.1.2 Global Nanomaterial-Based Adjuvants Vaccine Forecasted Sales by Type (2023-2028)

4.1.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2017-2028)

4.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type

4.2.1 Global Nanomaterial-Based Adjuvants Vaccine Historical Revenue by Type (2017-2022)

4.2.2 Global Nanomaterial-Based Adjuvants Vaccine Forecasted Revenue by Type (2023-2028)

4.2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2017-2028)

4.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Type

4.3.1 Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2017-2022)

4.3.2 Global Nanomaterial-Based Adjuvants Vaccine Price Forecast by Type (2023-2028)

5 Market Size by Application

5.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application

5.1.1 Global Nanomaterial-Based Adjuvants Vaccine Historical Sales by Application (2017-2022)

5.1.2 Global Nanomaterial-Based Adjuvants Vaccine Forecasted Sales by Application (2023-2028)

5.1.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2017-2028)

5.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application

5.2.1 Global Nanomaterial-Based Adjuvants Vaccine Historical Revenue by Application (2017-2022)

5.2.2 Global Nanomaterial-Based Adjuvants Vaccine Forecasted Revenue by Application (2023-2028)

5.2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2017-2028)

5.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Application

5.3.1 Global Nanomaterial-Based Adjuvants Vaccine Price by Application (2017-2022)

5.3.2 Global Nanomaterial-Based Adjuvants Vaccine Price Forecast by Application (2023-2028)

6 North America

6.1 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Type

6.1.1 North America Nanomaterial-Based Adjuvants Vaccine Sales by Type (2017-2028)

6.1.2 North America Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2017-2028)

6.2 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Application

6.2.1 North America Nanomaterial-Based Adjuvants Vaccine Sales by Application (2017-2028)

6.2.2 North America Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2017-2028)

6.3 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Country

6.3.1 North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2017-2028)

6.3.2 North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2017-2028)

6.3.3 United States

6.3.4 Canada

7 Europe

7.1 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Type

7.1.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Type (2017-2028)

7.1.2 Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2017-2028)

7.2 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Application

7.2.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Application (2017-2028)

7.2.2 Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2017-2028)

7.3 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Country

7.3.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2017-2028)

7.3.2 Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2017-2028)

7.3.3 Germany

7.3.4 France

7.3.5 U.K.

7.3.6 Italy

7.3.7 Russia

8 Asia Pacific

8.1 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Type

8.1.1 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Type (2017-2028)

8.1.2 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2017-2028)

8.2 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Application

8.2.1 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Application (2017-2028)

8.2.2 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2017-2028)

8.3 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Region

8.3.1 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (2017-2028)

8.3.2 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2017-2028)

8.3.3 China

8.3.4 Japan

8.3.5 South Korea

8.3.6 India

8.3.7 Australia

8.3.8 China Taiwan

8.3.9 Indonesia

8.3.10 Thailand

8.3.11 Malaysia

9 Latin America

9.1 Latin America Nanomaterial-Based Adjuvants Vaccine Market Size by Type

9.1.1 Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Type (2017-2028)

9.1.2 Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2017-2028)

9.2 Latin America Nanomaterial-Based Adjuvants Vaccine Market Size by Application

9.2.1 Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Application (2017-2028)

9.2.2 Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2017-2028)

9.3 Latin America Nanomaterial-Based Adjuvants Vaccine Market Size by Country

9.3.1 Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2017-2028)

9.3.2 Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2017-2028)

9.3.3 Mexico

9.3.4 Brazil

9.3.5 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Type

10.1.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Type (2017-2028)

10.1.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2017-2028)

10.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Application

10.2.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Application (2017-2028)

10.2.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2017-2028)

10.3 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Country

10.3.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2017-2028)

10.3.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2017-2028)

10.3.3 Turkey

10.3.4 Saudi Arabia

11 Company Profiles

11.1 Emergent BioSolutions

11.1.1 Emergent BioSolutions Corporation Information

11.1.2 Emergent BioSolutions Overview

11.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.1.5 Emergent BioSolutions Recent Developments

11.2 Sanofi

11.2.1 Sanofi Corporation Information

11.2.2 Sanofi Overview

11.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.2.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.2.5 Sanofi Recent Developments

11.3 GlaxoSmithKline Biologicals

11.3.1 GlaxoSmithKline Biologicals Corporation Information

11.3.2 GlaxoSmithKline Biologicals Overview

11.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.3.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.3.5 GlaxoSmithKline Biologicals Recent Developments

11.4 Merck

11.4.1 Merck Corporation Information

11.4.2 Merck Overview

11.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.4.4 Merck Nanomaterial-Based Adjuvants Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.4.5 Merck Recent Developments

11.5 Pfizer

11.5.1 Pfizer Corporation Information

11.5.2 Pfizer Overview

11.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.5.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.5.5 Pfizer Recent Developments

11.6 Novartis

11.6.1 Novartis Corporation Information

11.6.2 Novartis Overview

11.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.6.5 Novartis Recent Developments

11.7 Moderna

11.7.1 Moderna Corporation Information

11.7.2 Moderna Overview

11.7.3 Moderna Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)

11.7.4 Moderna Nanomaterial-Based Adjuvants Vaccine Product Model Numbers, Pictures, Descriptions and Specifications

11.7.5 Moderna Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Nanomaterial-Based Adjuvants Vaccine Industry Chain Analysis

12.2 Nanomaterial-Based Adjuvants Vaccine Key Raw Materials

12.2.1 Key Raw Materials

12.2.2 Raw Materials Key Suppliers

12.3 Nanomaterial-Based Adjuvants Vaccine Production Mode & Process

12.4 Nanomaterial-Based Adjuvants Vaccine Sales and Marketing

12.4.1 Nanomaterial-Based Adjuvants Vaccine Sales Channels

12.4.2 Nanomaterial-Based Adjuvants Vaccine Distributors

12.5 Nanomaterial-Based Adjuvants Vaccine Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

13.1 Nanomaterial-Based Adjuvants Vaccine Industry Trends

13.2 Nanomaterial-Based Adjuvants Vaccine Market Drivers

13.3 Nanomaterial-Based Adjuvants Vaccine Market Challenges

13.4 Nanomaterial-Based Adjuvants Vaccine Market Restraints

14 Key Findings in The Global Nanomaterial-Based Adjuvants Vaccine Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

Choose License Type

Checkout Inquiry Sample